Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

An Advanced Pneumatic Compression Therapy System Improves Leg Volume and Fluid, Adipose Tissue Thickness, Symptoms, and Quality of Life and Reduces Risk of Lymphedema in Women with Lipedema

Herbst KL., Zelaya C., Sommerville M., Zimmerman T., McHutchison L.

Laboratory Study with a reported sample of 22 on Knee, published in Life (Basel) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Life (Basel) (2025)
Reported sample size
22
Source database
Europe PMC
PMID
40430153
PMCID
PMC12113227
DOI
10.3390/life15050725
Citations
2

Abstract (original English)

Lipedema is a painful disease of subcutaneous adipose tissue (SAT) in women. This study determined whether an advanced pneumatic compression device (APCD) improved lipedema SAT depth, swelling, and pain. Women with lipedema started 20-30 mm Hg compression leggings then were randomized to an APCD (Lympha Press Optimal Plus) group for 30 days (treatment; n = 22) or a no APCD (Control; n = 24) group. APCD treatment significantly reduced left leg volume (3D imaging, LymphaTech; p p = 0.0018) and right legs ( p = 0.0476; SOZO, bioimpedance spectroscopy); controls showed no change. Treatment significantly decreased extracellular fluid (ECF) and intracellular fluid (ICF) in left ( p = 0.0077; p = 0.0060) and right legs ( p = 0.0476; p ≤ 0.025), respectively. Only ECF decreased significantly in the left ( p p = 0.0009) in controls. SAT depth decreased significantly by ultrasound after treatment at the anterior ( p ≤ 0.0234) and medial thigh ( p ≤ 0.0052), medial knee ( p ≤ 0.0002) and posterior calf ( p ≤ 0.0118) but not in controls. All signs and symptoms of lipedema improved in the treatment group including swelling ( p = 0.0005) and tenderness (pain) of right ( p = 0.0003) and left legs ( p p = 0.0377). In total, 87.5% of RAND SF-36 quality of life improved after treatment ( p ≤ 0.0351) compared to 37.5% in controls ( p ≤ 0.0475). APCDs are effective treatment for lipedema.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research